Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 6/20 | 0.62 |
| ▸ | GHSR | Q92847 | 3/20 | 0.62 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.59 |
| ▸ | IL1RN | P18510 | 1/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31619557 | 0.97 | IL23R (0.64) | KISS1RGHSRIL23R | |
| SCHEMBL30276251 | 0.97 | IL23R (0.64) | KISS1RGHSRIL23R | |
| SCHEMBL30276253 | 0.96 | GHSR (0.64) | KISS1RGHSRIL23R | |
| SCHEMBL29551293 | 0.96 | GHSR (0.64) | KISS1RGHSRIL23R | |
| SCHEMBL30276276 | 0.96 | GHSR (0.63) | KISS1RGHSRIL23R | |
| SCHEMBL30379397 | 0.95 | IL23R (0.64) | KISS1RGHSRIL23R | |
| SCHEMBL38662290 | 0.95 | IL23R (0.64) | KISS1RGHSRIL23R | |
| SCHEMBL30276250 | 0.95 | IL23R (0.65) | KISS1RGHSRIL23RNPY1RNPY2R | |
| SCHEMBL30276213 | 0.95 | IL23R (0.65) | KISS1RGHSRIL23RNPY1RNPY2R | |
| SCHEMBL30276242 | 0.94 | IL23R (0.63) | KISS1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025188678-A9 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250288611-A1 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. | 2025-09-18 | — | — | US | claimed |
| US-20250288611-A1 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. | 2025-09-18 | — | — | US | disclosed |
| US-11458206-B2 | Targeted conjugates and particles and formulations thereof | TVA (ABC), LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220251143-A1 | NON-HYDROLYZABLE NON-CLEAVABLE, STABLE LINKERS FOR PRECISION THERAPEUTICS AND USES THEREOF | UNIV COLUMBIA (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220096646-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-03-31 | — | — | US | disclosed |
| US-20220054647-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-02-24 | — | — | US | disclosed |
| CN-108473538-B | SSTR targeting conjugates and particles and formulations thereof | 塔弗达治疗有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3941508-A1 | NON-HYDROLYZABLE, NON-CLEAVABLE, STABLE LINKERS FOR PRECISION THERAPEUTICS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054647-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR1, SSTR4, SSTR3 | KISS1R 64/4885GHSR 13/4885IL23R 778/4885 |
| US-20220096646-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR1, SSTR4, SSTR3 | KISS1R 64/4885GHSR 13/4885IL23R 778/4885 |
| US-11458206-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | KISS1R 70/4885GHSR 19/4885IL23R 420/4885 |
| US-20220251143-A1 | NON-HYDROLYZABLE NON-CLEAVABLE, STABLE LINKERS FOR PRECISION THERAPEUTICS AND USES THEREOF | SSTR4, SSTR1, SSTR5 | KISS1R 478/4885GHSR 13/4885IL23R 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.